These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27277528)

  • 21. Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue.
    Lorenzi E; Simonelli M; Santoro A
    Crit Rev Oncol Hematol; 2016 Nov; 107():1-13. PubMed ID: 27823636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pattern approach for diseases of mesenteric small bowel on barium studies.
    Levine MS; Rubesin SE; Laufer I
    Radiology; 2008 Nov; 249(2):445-60. PubMed ID: 18812557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular toxicity of targeted therapies.
    Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
    J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.
    Mellor JD; Cassumbhoy M; Jefford M
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):106-13. PubMed ID: 21585689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
    Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
    Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents.
    Chikarmane SA; Khurana B; Krajewski KM; Shinagare AB; Howard S; Sodickson A; Jagannathan J; Ramaiya N
    Emerg Radiol; 2012 Dec; 19(6):535-46. PubMed ID: 22673844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy.
    Nesher L; Rolston KV
    Clin Infect Dis; 2013 Mar; 56(5):711-7. PubMed ID: 23196957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The gastrointestinal complications of oncologic therapy.
    Shafi MA; Bresalier RS
    Gastroenterol Clin North Am; 2010 Sep; 39(3):629-47. PubMed ID: 20951921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing Adverse Events With Immune Checkpoint Agents.
    Dadu R; Zobniw C; Diab A
    Cancer J; 2016; 22(2):121-9. PubMed ID: 27111908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms for vascular complications of targeted cancer therapies.
    Gopal S; Miller KB; Jaffe IZ
    Clin Sci (Lond); 2016 Oct; 130(20):1763-79. PubMed ID: 27612952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors.
    Alessandrino F; Tirumani SH; Krajewski KM; Shinagare AB; Jagannathan JP; Ramaiya NH; Di Salvo DN
    Clin Radiol; 2017 Jul; 72(7):521-533. PubMed ID: 28476244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.
    Sundararajan S; Kumar A; Poongkunran M; Kannan A; Vogelzang NJ
    Future Oncol; 2016; 12(8):1067-80. PubMed ID: 26901457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis.
    Birch JC; Khatri G; Watumull LM; Arriaga YE; Leyendecker JR
    Radiographics; 2018; 38(4):1158-1179. PubMed ID: 29995613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sclerosing mesenteritis mimicking metachronous peritoneal metastases from descending colon adenocarcinoma.
    Watanabe T; Terai S; Tsukada T; Takeshita M; Matsui K; Amaya K; Kaji M; Maeda K; Shimizu K; Saito J; Mochizuki K; Uchiyama A
    World J Surg Oncol; 2017 Aug; 15(1):142. PubMed ID: 28764712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CT of blunt trauma to the bowel and mesentery.
    Nghiem HV; Jeffrey RB; Mindelzun RE
    AJR Am J Roentgenol; 1993 Jan; 160(1):53-8. PubMed ID: 8416646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular toxicity associated with chemotherapy and molecular targeted therapy: what should a radiologist know?
    Rohatgi S; Jagannathan JP; Rosenthal MH; Kim KW; Ramaiya NH; Krajewski KM
    AJR Am J Roentgenol; 2014 Dec; 203(6):1353-62. PubMed ID: 25415715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines.
    Hirakawa A; Sudo K; Yonemori K; Sadachi R; Kinoshita F; Kobayashi Y; Okuma HS; Kawachi A; Tamura K; Fujiwara Y; Rubinstein L; Takebe N
    Clin Pharmacol Ther; 2019 Oct; 106(4):803-809. PubMed ID: 30927439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Managing cutaneous toxicities of targeted therapies].
    Kiyohara Y
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].
    Matzka M; Stöhr D; Colditz A; Köck-Hódi S; Koller M; Mayer H
    Pflege; 2017 Jan; 30(1):9-17. PubMed ID: 27901405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.